Your browser is no longer supported. Please, upgrade your browser.
Settings
PASG [NASD]
Passage Bio, Inc.
Index- P/E- EPS (ttm)-2.56 Insider Own0.60% Shs Outstand45.50M Perf Week10.34%
Market Cap1.00B Forward P/E- EPS next Y-2.92 Insider Trans-0.42% Shs Float23.39M Perf Month-6.54%
Income-86.40M PEG- EPS next Q-0.70 Inst Own70.30% Short Float8.41% Perf Quarter-11.76%
Sales- P/S- EPS this Y-257.30% Inst Trans3.44% Short Ratio4.30 Perf Half Y18.69%
Book/sh7.45 P/B2.61 EPS next Y-5.10% ROA- Target Price28.50 Perf Year-5.68%
Cash/sh6.49 P/C2.99 EPS next 5Y- ROE- 52W Range8.09 - 38.23 Perf YTD-24.01%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.18% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low140.17% ATR1.70
Employees20 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)44.53 Volatility9.73% 8.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-116.90% Profit Margin- Rel Volume0.89 Prev Close19.96
ShortableYes LT Debt/Eq0.00 EarningsMar 03 BMO Payout- Avg Volume457.43K Price19.43
Recom1.70 SMA20-3.94% SMA50-16.10% SMA200-5.75% Volume408,478 Change-2.66%
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Jun-25-20Downgrade Goldman Buy → Neutral $28
Mar-25-20Initiated Chardan Capital Markets Buy $30
Mar-24-20Initiated JP Morgan Overweight $25
Mar-24-20Initiated Goldman Buy $27
Mar-24-20Initiated Cowen Outperform
Mar-03-21 07:00AM  
06:30AM  
Mar-02-21 04:01PM  
Feb-24-21 07:00AM  
Feb-19-21 07:00AM  
Feb-08-21 07:00AM  
Feb-04-21 12:04PM  
10:03AM  
Jan-28-21 07:00AM  
03:00AM  
Jan-22-21 02:22PM  
Jan-21-21 07:48PM  
Jan-19-21 04:06PM  
07:00AM  
Jan-13-21 10:25AM  
Jan-11-21 07:00AM  
Jan-04-21 04:01PM  
07:00AM  
Dec-16-20 08:00AM  
Dec-15-20 11:10PM  
Dec-11-20 08:11AM  
Dec-10-20 04:01PM  
Dec-07-20 07:00AM  
Nov-24-20 03:55AM  
Nov-23-20 04:01PM  
Nov-11-20 04:30PM  
07:00AM  
Nov-10-20 07:00AM  
Nov-09-20 07:00AM  
Nov-04-20 07:00AM  
Oct-28-20 07:00AM  
Oct-26-20 07:00AM  
Oct-14-20 08:30AM  
Oct-13-20 04:30PM  
Oct-06-20 07:00AM  
Sep-25-20 07:00AM  
Sep-17-20 07:00AM  
Sep-03-20 08:00AM  
Aug-26-20 02:58PM  
Aug-13-20 07:00AM  
Aug-07-20 04:01PM  
Jun-26-20 08:00AM  
Jun-04-20 11:17AM  
08:00AM  
May-28-20 08:35AM  
May-21-20 08:00AM  
May-12-20 05:00PM  
May-11-20 07:00AM  
May-07-20 07:30AM  
May-04-20 08:00AM  
Apr-21-20 08:00AM  
Apr-08-20 08:00AM  
Mar-27-20 08:00AM  
Mar-09-20 04:30PM  
Mar-05-20 08:00AM  
Feb-27-20 07:25PM  
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin for the treatment of FTD caused by a deficiency of progranulin; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase, for infantile Krabbe disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Quigley Jill M.Chief Operating OfficerJan 20Sale30.011,30039,011295,284Jan 22 05:54 PM